Prenetics Global Limited (PRE) Q3 Revenue Rose 228% YoY; Raises H2 EBITDA Loss Outlook

Prenetics reported Q3 2026 revenue of $64.1M, up 228% YoY, with a quarterly loss of $25.4M. The company raised its H2 EBITDA loss outlook to $30–35M, up from $8–12M, while reaffirming FY2026 revenue guidance of $220–230M and FY2027 IM8 revenue guidance of $400M or more.

Original reporting
Published Nov 18, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prenetics Global Limited (PRE) Q3 Revenue Rose 228% YoY; Raises H2 EBITDA Loss Outlook — source image
Decision brief

The 30-second read

$PRENeutralMed
01

Why it matters

The key trading variable is the step-up in expected H2 Adjusted EBITDA loss to $30–35M, which can pressure valuation multiples even as revenue guidance is reaffirmed.

02

Market read

Traders will likely focus on whether the higher spending implied by the loss outlook is consistent with sustained revenue growth and improving acquisition efficiency.

03

What to watch

The article does not provide customer-acquisition return metrics or cash burn details, so traders may overreact to EBITDA loss without confirming whether the spending is translating into durable revenue acceleration.

Relevance 8/10Novelty 7/10Timing: ahead of next quarterly read-through, after-hours/next-session positioning based on updated H2 loss outlook

Background

Prenetics is reporting another quarter of rapid revenue growth while adjusting its second-half profitability outlook.

Company-level read

Ticker impact

$PRENeutralHigh confidence
Context

Prenetics reported Q3 2026 revenue of $64.1M (+228% YoY) and guided H2 Adjusted EBITDA loss of $30–35M, versus $8–12M expected in August.

Expected impact

Likely mixed-to-negative near-term reaction as investors reprice the larger-than-expected loss trajectory despite reaffirmed revenue targets.

Evidence & confidence

The article discloses both a strong top-line print and a clear, updated loss outlook for the second half, which typically drives valuation and risk sentiment more than revenue growth alone.

Market effects

Signals heightened spending and execution risk in consumer health diagnostics/healthtech models where acquisition costs can pressure EBITDA before scaling.

No specific regional market catalyst beyond the issuer’s own guidance.

Limited, company-specific guidance update with no stated cross-border policy or supply-chain shock.

Counterpoint

The wider H2 EBITDA loss may reflect deliberate investment to sustain the very high YoY revenue growth, which could improve future unit economics if customer-acquisition payback shortens.

Key entities

  • Prenetics Global Limited

    Reported Q3 2026 revenue growth and raised its expected H2 Adjusted EBITDA loss range while reaffirming FY2026 revenue guidance.

Related articles

$PREMedAI 8/10

Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

$PREMed

Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.